CAJ | 학술논문

目的评价芳香化酶抑制剂(AI)治疗绝经后转移性乳腺癌患者的临床疗效及预后.方法 2010年1月至2014年4月在河南省肿瘤医院接受AI(包括阿那曲唑、来曲唑和依西美坦)治疗的148例绝经后(包括双侧卵巢切除手术)激素受体阳性的晚期乳腺癌患者,进行临床疗效评价.结果全组患者的中位无进展生存时间(PFS)为6.5个月,临床获益率(CBR)为68.2％.接受一线内分泌治疗患者的中位PFS为9.0个月(95％ CI:6.95～ 11.05个月),接受二线及以上内分泌治疗患者的中位PFS为3.0个月(95％ CI:1.8 ～ 10.1个月),两者差异有统计学意义(P=0.000);CBR分别为80.9％和28.6％,差异均有统计学意义(均P＜0.05).结论 AI治疗绝经后激素受体阳性的转移性乳腺癌患者临床疗效肯定,可作为一线治疗的选择.
목적 평개방향화매억제제(AI)치료절경후전이성유선암환자적림상료효급예후.방법 2010년1월지2014년4월재하남성종류의원접수AI(포괄아나곡서、래곡서화의서미탄)치료적148례절경후(포괄쌍측란소절제수술)격소수체양성적만기유선암환자,진행림상료효평개.결과 전조환자적중위무진전생존시간(PFS)위6.5개월,림상획익솔(CBR)위68.2％.접수일선내분비치료환자적중위PFS위9.0개월(95％ CI:6.95～ 11.05개월),접수이선급이상내분비치료환자적중위PFS위3.0개월(95％ CI:1.8 ～ 10.1개월),량자차이유통계학의의(P=0.000);CBR분별위80.9％화28.6％,차이균유통계학의의(균P＜0.05).결론 AI치료절경후격소수체양성적전이성유선암환자림상료효긍정,가작위일선치료적선택.
Objective To evaluate the clinical efficacies of aromatase inhibitors in the treatment of postmenopausal metastatic breast cancer.Methods A total of 148 postmenopausal women (including bilateral ovariectomy) with hormone dependent metastatic breast cancer receiving aromatase inhibitors (letrozole,anastrozole or exemestane) were analyzed retrospectively.Their clinical efficacies were evaluated.Results The median progression-free survival (PFS) was 6.5 months and the clinical benefit rate 63.5％.And the rates of PFS of patients on first-line and second-line or above treatments were 9.0 (95 ％ CI:6.95-11.05) and 3.0 months (95 ％ CI:1.8-10.1) respectively.The clinical benefit rates of two groups were 74.2％ and 26.3％ respectively.Conclusion Aromatase inhibitors are both efficacious and well-tolerated for patients of postmenopausal metastatic breast cancer.It may be recommended as a first-line therapy for postmenopausal women with hormone dependent metastatic breast cancer.